David Jakeman - Chimerix Director
| CMRX Stock | USD 0.91 0.02 2.15% |
Director
Mr. David Jakeman, CPA is Principal Accounting Officer, Executive Director of Finance and Accounting of the Company. Mr. Jakeman has worked in various financerelated roles at the Company since 2009, most recently serving as the Companys Director of Finance since January 2011. Prior to joining the Company, from 2000 to 2009, Mr. Jakeman worked at Ernst Young LLP in their assurance practice since 2019.
| Age | 41 |
| Tenure | 5 years |
| Address | 2505 Meridian Parkway, Durham, NC, United States, 27713 |
| Phone | 919-806-1074 |
| Web | https://www.chimerix.com |
Latest Insider Transactions
Jakeman earned a BS in Business Administration and a Masters in Accounting from the University of North Carolina at Chapel Hill.Chimerix Management Efficiency
The company has return on total asset (ROA) of (0.2364) % which means that it has lost $0.2364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.365) %, meaning that it created substantial loss on money invested by shareholders. Chimerix's management efficiency ratios could be used to measure how well Chimerix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.5 in 2024. At this time, Chimerix's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 421.1 K in 2024, whereas Total Assets are likely to drop slightly above 197 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Fiona Oliver | Instil Bio | N/A | |
| Timothy Shannon | CytomX Therapeutics | 56 | |
| Mark Auerbach | Assembly Biosciences | 78 | |
| Richard DiMarchi | Assembly Biosciences | 64 | |
| JeanFranois Formela | Spero Therapeutics | 61 | |
| Patrick Vink | Spero Therapeutics | 54 | |
| Phillip Strachan | Instil Bio | N/A | |
| Alan Lewis | Assembly Biosciences | 71 | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| John Pottage | Spero Therapeutics | N/A | |
| Manju Mazumder | Instil Bio | N/A | |
| Frederick Gluck | CytomX Therapeutics | 82 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
| Gaurav Swarup | Instil Bio | 60 | |
| Murray Stewart | X4 Pharmaceuticals | 57 | |
| Susan Mahony | Assembly Biosciences | 52 | |
| Neil Exter | CytomX Therapeutics | 57 | |
| Aloke Banerjee | Instil Bio | 61 | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
| Charles Fuchs | CytomX Therapeutics | 57 | |
| Ramana Rao | Instil Bio | N/A | |
Management Performance
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.24 |
Chimerix Leadership Team
Elected by the shareholders, the Chimerix's board of directors comprises two types of representatives: Chimerix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chimerix. The board's role is to monitor Chimerix's management team and ensure that shareholders' interests are well served. Chimerix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chimerix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MBA, President CEO | ||
| Joshua Allen, Chief Imipridones | ||
| Dr MBA, Chief Officer | ||
| Patrick Machado, Independent Director | ||
| Timothy Wollaeger, Independent Director | ||
| Michael Sherman, CEO | ||
| Williams Nichols, Chief Medical Officer | ||
| Heather KnightTrent, Vice President - Regulatory Affairs | ||
| Ronald Renaud, Director | ||
| John Leonard, Director | ||
| Linda Richardson, Chief Commercial Officer | ||
| Timothy Trost, CFO, Senior Vice President Corporate Secretary | ||
| David Jakeman, Principal Accounting Officer, Executive Director of Finance and Accounting | ||
| Michael Rogers, Chief Devel. Officer | ||
| Fred Middleton, Director | ||
| James Daly, Director | ||
| James Niedel, Independent Director | ||
| Roy Ware, Chief Manufacturing and Technology Officer | ||
| Michael Andriole, Chief Business Officer | ||
| Dr JD, General VP | ||
| Michelle LaSpaluto, Chief Officer | ||
| Clarence Machado, Independent Director | ||
| Ernest Mario, Non-Executive Independent Chairman of the Board | ||
| Randall Lanier, Chief Science Officer | ||
| MD MBA, Chief Officer | ||
| Catherine Gilliss, Director | ||
| Michelle Berrey, President CEO, Chief Medical Officer, Director | ||
| David CPA, Exec Officer | ||
| Joseph Schepers, Executive Director of Investor Relations and Corporate Communications | ||
| Michael Alrutz, interim CEO, Senior Vice President General Counsel | ||
| Garrett Nichols, Chief Medical Officer | ||
| Pablo MD, Head Affairs | ||
| Martha Demski, Independent Director | ||
| Thomas Riga, Chief Officer | ||
| Lisa Ricciardi, Independent Director | ||
| Robert Meyer, Director | ||
| Edward Greissing, Director |
Chimerix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chimerix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | (98.47 M) | ||||
| Shares Outstanding | 89.21 M | ||||
| Shares Owned By Insiders | 1.34 % | ||||
| Shares Owned By Institutions | 50.01 % | ||||
| Number Of Shares Shorted | 1.24 M | ||||
| Price To Earning | (3.43) X | ||||
| Price To Book | 0.44 X | ||||
| Price To Sales | 264.52 X |
Pair Trading with Chimerix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chimerix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chimerix will appreciate offsetting losses from the drop in the long position's value.Moving against Chimerix Stock
| 0.54 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.47 | CGC | Canopy Growth Corp Trending | PairCorr |
The ability to find closely correlated positions to Chimerix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chimerix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chimerix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chimerix to buy it.
The correlation of Chimerix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chimerix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chimerix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chimerix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chimerix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Chimerix Stock please use our How to Invest in Chimerix guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Chimerix Stock analysis
When running Chimerix's price analysis, check to measure Chimerix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimerix is operating at the current time. Most of Chimerix's value examination focuses on studying past and present price action to predict the probability of Chimerix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimerix's price. Additionally, you may evaluate how the addition of Chimerix to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Chimerix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chimerix. If investors know Chimerix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chimerix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 0.004 | Quarterly Revenue Growth (0.99) | Return On Assets (0.24) | Return On Equity (0.36) |
The market value of Chimerix is measured differently than its book value, which is the value of Chimerix that is recorded on the company's balance sheet. Investors also form their own opinion of Chimerix's value that differs from its market value or its book value, called intrinsic value, which is Chimerix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chimerix's market value can be influenced by many factors that don't directly affect Chimerix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chimerix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Chimerix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chimerix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.